Advertisement

Diffuse large B-cell lymphoma

Published:November 20, 2017DOI:https://doi.org/10.1016/j.pathol.2017.09.006

      Summary

      Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30–40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites. The most common type of DLBCL, designated as not otherwise specified, represents 80–85% of all cases and is the focus of this review. There are also rare types of lymphoma composed of large B-cells, in aggregate about 15–20% of all neoplasms that are sufficiently distinctive to recognise separately. DLBCL not otherwise specified (referred to henceforth as DLBCL) is a heterogeneous entity in terms of clinical presentation, genetic findings, response to therapy, and prognosis. A major advance was the application of gene expression profiling (GEP) to the study of DLBCL which further clarified this heterogeneity and provided a rationale for subdividing cases into groups. The most popular system divides cases of DLBCL according to cell-of-origin into germinal centre B-cell like (GCB) and activated B-cell like (ABC) subtypes, with about 10–15% of cases being unclassifiable. Patients with the GCB subtype usually have better prognosis than patients with the ABC subtype. Although cell-of-origin is useful for predicting outcome, the GCB and ABC subtypes remain heterogeneous, with better and worse prognostic subsets within each group. Next generation sequencing (NGS) analysis of DLBCL has facilitated global identification of numerous and diverse genetic abnormalities in these neoplasms and has shown that GCB and ABC tumours have different mutation profiles. Although the therapy of patients with DLBCL is an active area of research, the current 5-year overall survival rate is 60–70% using standard-of-care frontline therapy. A precision medicine approach for the design of new therapies based on molecular findings in DLBCL is likely the best path forward. As pathologists, our role has expanded beyond diagnosis. We must perform a complete work-up of DLBCL cases. In addition to our traditional role in establishing the diagnosis, we need to analyse markers that provide information regarding prognosis and potential therapeutic targets. We also must ensure that adequate tissue is triaged for molecular studies which are essential for designing therapy regimens, particularly in the setting of disease relapse.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rappaport H.
        Tumors of the Hematopoeitic System.
        Armed Forces Institute of Pathology, Washington DC1966
        • Smith J.L.
        • Clein G.P.
        • Barker C.R.
        • Collins R.D.
        Characterisation of malignant mediastinal lymphoid neoplasm (Sternberg sarcoma) as thymic in origin.
        Lancet. 1973; 1: 74-77
        • Jaffe E.S.
        • Shevach E.M.
        • Frank M.M.
        • Berard C.W.
        • Green I.
        Nodular lymphoma—evidence for origin from follicular B lymphocytes.
        N Engl J Med. 1974; 290: 813-819
        • Lennert K.
        • Stein H.
        • Kaiserling E.
        Cytological and functional criteria for the classification of malignant lymphomata.
        Br J Cancer Suppl. 1975; 2: 29-43
        • Lukes R.J.
        • Collins R.D.
        Immunologic characterization of human malignant lymphomas.
        Cancer. 1974; : 1488-1503
        • Taylor C.R.
        • Hartsock R.J.
        Classifications of lymphoma; reflections of time and technology.
        Virchows Arch. 2011; 458: 637-648
        • Pizzi M.
        • Gazzola A.
        • Mannu C.
        • et al.
        The role of molecular biology in the diagnosis of lymphoid neoplasms.
        Front Biosci. 2014; 19: 1088-1104
      1. Swerdlow S.H. Campo E. Harris N.L. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC, Lyon2008
        • Swerdlow S.H.
        • Campo E.
        • Pileri S.A.
        • et al.
        The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
        Blood. 2016; 127: 2375-2390
        • Perry A.M.
        • Diebold J.
        • Nathwani B.N.
        • et al.
        Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project.
        Haematologica. 2016; 101: 1244-1250
        • Teras L.R.
        • DeSantis C.E.
        • Cerhan J.R.
        • Morton L.M.
        • Jemal A.
        • Flowers C.R.
        2016 US lymphoid malignancy statistics by World Health Organization subtypes.
        CA Cancer J Clin. 2016; 66: 443-459
        • Martelli M.
        • Ferreri A.J.
        • Agostinelli C.
        • Di Rocco A.
        • Pfreundschuh M.
        • Pileri S.A.
        Diffuse large B-cell lymphoma.
        Crit Rev Oncol Hematol. 2013; 87: 146-171
        • Yao Z.
        • Deng L.
        • Xu-Monette Z.Y.
        • et al.
        Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
        Leukemia. 2017; Jul 12 (Epub ahead of print). https://doi.org/10.1038/leu.2017.222
        • Brudno J.
        • Tadmor T.
        • Pittaluga S.
        • Nicolae A.
        • Polliack A.
        • Dunleavy K.
        Discordant bone marrow involvement in non-Hodgkin lymphoma.
        Blood. 2016; 127: 965-970
        • Korkolopoulou P.
        • Vassilakopoulos T.
        • Milionis V.
        • Ioannou M.
        Recent advances in aggressive large B-cell lymphomas: a comprehensive review.
        Adv Anat Pathol. 2016; 23: 202-243
        • Horn H.
        • Staiger A.M.
        • Vohringer M.
        • et al.
        Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.
        Am J Surg Pathol. 2015; 39: 61-66
        • Loddenkemper C.
        • Anagnostopoulos I.
        • Hummel M.
        • et al.
        Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
        J Pathol. 2004; 202: 60-69
        • Hu S.
        • Xu-Monette Z.Y.
        • Balasubramanyam A.
        • et al.
        CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
        Blood. 2013; 121: 2715-2724
        • Georgiou K.
        • Chen L.
        • Berglund M.
        • et al.
        Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
        Blood. 2016; 127: 3026-3034
        • Tagawa H.
        • Suguro M.
        • Tsuzuki S.
        • et al.
        Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma.
        Blood. 2005; 106 (Erratum in: Blood 2006; 107: 3052): 1770-1777
        • Chen W.
        • Houldsworth J.
        • Olshen A.B.
        • et al.
        Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas.
        Blood. 2006; 107: 2477-2485
        • Karube K.
        • Enjuanes A.
        • Dlouhy I.
        • et al.
        Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
        Leukemia. 2017; Aug 14 (Epub ahead of print). https://doi.org/10.1038/leu.2017.251
        • Offit K.
        • Lo Coco F.
        • Louie D.C.
        • et al.
        Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.
        N Engl J Med. 1994; 331: 74-80
        • Kramer M.H.
        • Hermans J.
        • Wijburg E.
        • et al.
        Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
        Blood. 1998; 92: 3152-3162
        • Barrans S.
        • Crouch S.
        • Smith A.
        • et al.
        Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
        J Clin Oncol. 2010; 28: 3360-3365
        • Pasqualucci L.
        • Trifonov V.
        • Fabbri G.
        • et al.
        Analysis of the coding genome of diffuse large B-cell lymphoma.
        Nat Genet. 2011; 43: 830-837
        • Alizadeh A.A.
        • Eisen M.B.
        • Davis R.E.
        • et al.
        Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
        Nature. 2000; 403: 503-511
        • Rosenwald A.
        • Wright G.
        • Chan W.C.
        • et al.
        The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
        N Engl J Med. 2002; 346: 1937-1947
        • Monti S.
        • Savage K.J.
        • Kutok J.L.
        • et al.
        Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
        Blood. 2005; 105: 1851-1861
        • Dybkær K.
        • Bøgsted M.
        • Falgreen S.
        • et al.
        Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
        J Clin Oncol. 2015; 33: 1379-1388
        • Lenz G.
        • Wright G.
        • Dave S.S.
        • et al.
        Stromal gene signatures in large-B-cell lymphomas.
        N Engl J Med. 2008; 359: 2313-2323
        • Clozel T.
        • Yang S.
        • Elstrom R.L.
        • et al.
        Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
        Cancer Discov. 2013; 3: 1002-1019
        • Perry A.M.
        • Cardesa-Salzmann T.M.
        • Meyer P.N.
        • et al.
        A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma.
        Blood. 2012; 120: 2290-2296
        • Morin R.D.
        • Mungall K.
        • Pleasance E.
        • et al.
        Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing.
        Blood. 2013; 122: 1256-1265
        • Compagno M.
        • Lim W.K.
        • Grunn A.
        • et al.
        Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
        Nature. 2009; 459: 717-721
        • Davis R.E.
        • Ngo V.N.
        • Lenz G.
        • et al.
        Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
        Nature. 2010; 463: 88-92
        • Ngo V.N.
        • Young R.M.
        • Schmitz R.
        • et al.
        Oncogenically active MYD88 mutations in human lymphoma.
        Nature. 2011; 470: 115-119
        • Pasqualucci L.
        • Dominguez-Sola D.
        • Chiarenza A.
        • et al.
        Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
        Nature. 2011; 471: 189-195
        • Zhang J.
        • Grubor V.
        • Love C.L.
        • et al.
        Genetic heterogeneity of diffuse large B-cell lymphoma.
        Proc Natl Acad Sci USA. 2013; 110: 1398-1403
        • Lee J.H.
        • Jeong H.
        • Choi W.W.
        • Oh H.
        • Kim Y.S.
        Clinopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
        Sci Rep. 2017; 7: 1785
        • Young K.H.
        • Weisenburger D.D.
        • Dave B.J.
        • et al.
        Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
        Blood. 2007; 110: 4396-4405
        • International Non-Hodgkin's Lymphoma Prognostic Factors Project
        A predictive model for aggressive non-Hodgkin's lymphoma.
        N Engl J Med. 1993; 329: 987-994
        • Zhou Z.
        • Sehn L.H.
        • Rademaker A.W.
        • et al.
        An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
        Blood. 2014; 12: 837-842
        • Ott G.
        • Ziepert M.
        • Klapper W.
        • et al.
        Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
        Blood. 2010; 116: 4916-4925
        • Li M.
        • Liu Y.
        • Wang Y.
        • et al.
        Anaplastic variant of diffuse large B-cell lymphoma displays intricate genetic alterations and distinct biological features.
        Am J Surg Pathol. 2017; 41: 1322-1332
        • Schmidt-Hansen M.
        • Berendse S.
        • Marafioti T.
        • McNamara C.
        Does cell-of-origin or MYC, BCL2 or PCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.
        Leuk Lymphoma. 2017; 58: 2403-2418
        • Hans C.P.
        • Weisenburger D.D.
        • Greiner T.C.
        • et al.
        Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
        Blood. 2004; 103: 275-282
        • Choi W.W.
        • Weisenburger D.D.
        • Greiner T.C.
        • et al.
        A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
        Clin Cancer Res. 2009; 15: 5494-5502
        • Visco C.
        • Li Y.
        • Xu-Monette Z.Y.
        • et al.
        Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
        Leukemia. 2012; 26: 2103-2113
        • Meyer P.N.
        • Fu K.
        • Greiner T.C.
        • et al.
        Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
        J Clin Oncol. 2011; 29: 200-207
        • Muris J.J.
        • Meijer C.J.
        • Vos W.
        • et al.
        Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
        J Pathol. 2006; 208: 714-723
        • Nyman H.
        • Adde M.
        • Karjalainen-Lindsberg M.L.
        • et al.
        Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
        Blood. 2007; 109: 4930-4935
        • Scott D.W.
        • Wright G.W.
        • Williams P.M.
        • et al.
        Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
        Blood. 2014; 123: 1214-1217
        • Nie Z.
        • Hu G.
        • Wei G.
        • et al.
        c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.
        Cell. 2012; 151: 68-79
        • Nguyen L.
        • Papenhausen P.
        • Shao H.
        The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects.
        Genes (Basel). 2017; 8
        • Horn H.
        • Ziepert M.
        • Becher C.
        • et al.
        MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
        Blood. 2013; 121: 2253-2263
        • Lin P.
        • Dickason T.J.
        • Fayad L.E.
        • et al.
        Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
        Cancer. 2012; 118: 1566-1573
        • Landsburg D.J.
        • Falkiewicz M.K.
        • Petrich A.M.
        • et al.
        Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
        Br J Haematol. 2016; 175: 631-640
        • Li S.
        • Weiss V.L.
        • Wang X.J.
        • et al.
        High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis.
        Am J Surg Pathol. 2016; 40: 253-261
        • Epperla N.
        • Maddocks K.J.
        • Salhab M.
        • et al.
        C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: impact of additional “hits” and outcomes with subsequent therapy.
        Cancer. 2017; 123: 4411-4418
        • Copie-Bergman C.
        • Cuillière-Dartigues P.
        • Baia M.
        • et al.
        MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
        Blood. 2015; 126: 2466-2474
        • Pedersen M.O.
        • Gang A.O.
        • Poulsen T.S.
        • et al.
        MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.
        Eur J Haematol. 2014; 92: 42-48
        • Moore E.M.
        • Aggarwal N.
        • Surti U.
        • Swerdlow S.H.
        Further exploration of the complexities of large B-cell lymphomas with MYC abnormalities and the importance of a blastoid morphology.
        Am J Surg Pathol. 2017; 41: 1155-1166
        • Lu T.X.
        • Fan L.
        • Wang L.
        • et al.
        MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.
        Oncotarget. 2015; 6: 18374-18388
        • Quesada A.E.
        • Medeiros L.J.
        • Desai P.A.
        • et al.
        Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
        Mod Pathol. 2017; Aug 4 (Epub ahead of print). https://doi.org/10.1038/modpathol.2017.93
        • Visco C.
        • Tzankov A.
        • Xu-Monette Z.Y.
        • et al.
        Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome,irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
        Haematologica. 2013; 98: 255-263
        • Naeini Y.B.
        • Wu A.
        • O'Malley D.P.
        Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population.
        Ann Diagn Pathol. 2016; 25: 7-14
        • Aukema S.M.
        • Siebert R.
        • Schuuring E.
        • et al.
        Double-hit B-cell lymphomas.
        Blood. 2011; 117: 2319-2331
        • Wang W.
        • Hu S.
        • Lu X.
        • Young K.H.
        • Medeiros L.J.
        Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases.
        Am J Surg Pathol. 2015; 39: 1132-1139
        • Li S.
        • Saksena A.
        • Desai P.
        • et al.
        Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma.
        Oncotarget. 2016; 7: 38122-38132
        • Landsburg D.J.
        • Petrich A.M.
        • Abramson J.S.
        • et al.
        Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
        Cancer. 2016; 122: 559-564
        • Kanungo A.
        • Medeiros L.J.
        • Abruzzo L.V.
        • Lin P.
        Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis.
        Mod Pathol. 2006; 19: 25-33
        • Le Gouill S.
        • Talmant P.
        • Touzeau C.
        • et al.
        The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
        Haematologica. 2007; 92: 1335-1342
        • Tomita N.
        • Tokunaka M.
        • Nakamura N.
        • et al.
        Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
        Haematologica. 2009; 94: 935-943
        • Johnson N.A.
        • Savage K.J.
        • Ludkovski O.
        • et al.
        Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
        Blood. 2009; 114: 2273-2279
        • Niitsu N.
        • Okamoto M.
        • Miura I.
        • Hirano M.
        Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
        Leukemia. 2009; 23: 777-783
        • Li S.
        • Lin P.
        • Fayad L.E.
        • et al.
        B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
        Mod Pathol. 2012; 25: 145-156
        • Pedersen M.O.
        • Gang A.O.
        • Poulsen T.S.
        • et al.
        Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma – a single centre's experience.
        Eur J Haematol. 2012; 89: 63-71
        • Lin P.
        • Medeiros L.J.
        High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis.
        Haematologica. 2007; 92: 1297-1301
        • Oki Y.
        • Noorani M.
        • Lin P.
        • et al.
        Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
        Br J Haematol. 2014; 166: 891-901
        • Landsburg D.J.
        • Falkiewicz M.K.
        • Maly J.
        • et al.
        Outcomes of patients with double-hit lymphoma who achieve first complete remission.
        J Clin Oncol. 2017; 35: 2260-2267
        • Petrich A.M.
        • Gandhi M.
        • Jovanovic B.
        • et al.
        Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
        Blood. 2014; 124: 2354-2361
        • Pillai R.K.
        • Sathanoori M.
        • Van Oss S.B.
        • Swerdlow S.H.
        Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
        Am J Surg Pathol. 2013; 37: 323-332
        • Turakhia S.K.
        • Hill B.T.
        • Dufresne S.D.
        • Nakashima M.O.
        • Cotta C.V.
        Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.
        Am J Clin Pathol. 2014; 142: 339-346
        • Li S.
        • Desai P.
        • Lin P.
        • et al.
        MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
        Histopathology. 2016; 68: 1090-1098
        • Aukema S.M.
        • Kreuz M.
        • Kohler C.W.
        • et al.
        Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.
        Haematologica. 2014; 99: 726-735
        • Li S.
        • Seegmiller A.C.
        • Lin P.
        • et al.
        B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
        Mod Pathol. 2015; 28: 208-217
        • Johnson N.A.
        • Slack G.W.
        • Savage K.J.
        • et al.
        Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
        J Clin Oncol. 2012; 30: 3452-3459
        • Hu S.
        • Xu-Monette Z.Y.
        • Tzankov A.
        • et al.
        MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program.
        Blood. 2013; 121: 4021-4031
        • Wang X.J.
        • Medeiros L.J.
        • Lin P.
        • et al.
        MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
        Am J Surg Pathol. 2015; 39: 1250-1258
        • Xu-Monette Z.Y.
        • Medeiros L.J.
        • Li Y.
        • et al.
        Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
        Blood. 2012; 119: 3668-3683
        • Ichikawa A.
        • Kinoshita T.
        • Watanabe T.
        • et al.
        Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
        N Engl J Med. 1997; 337: 529-534
        • Kerbauy F.R.
        • Colleoni G.W.
        • Saad S.T.
        • et al.
        Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.
        Leuk Lymphoma. 2004; 45: 2071-2078
        • Xu-Monette Z.Y.
        • Wu L.
        • Visco C.
        • et al.
        Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
        Blood. 2012; 120: 3986-3996
        • Gebauer N.
        • Bernard V.
        • Gebauer W.
        • Thorns C.
        • Feller A.C.
        • Merz H.
        TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
        Leuk Lymphoma. 2015; 56: 179-185
        • Xie Y.
        • Bulbul M.A.
        • Ji L.
        • et al.
        p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
        Am J Clin Pathol. 2014; 141: 593-604
        • Wang X.J.
        • Medeiros L.J.
        • Bueso-Ramos C.E.
        • et al.
        P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
        Mod Pathol. 2017; 30: 194-203
        • Clipson A.
        • Barrans S.
        • Zeng N.
        • et al.
        The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.
        J Pathol Clin Res. 2015; 1: 125-133
        • Yamaguchi M.
        • Seto M.
        • Okamoto M.
        • et al.
        De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
        Blood. 2002; 99: 815-821
        • Xu-Monette Z.Y.
        • Tu M.
        • Jabbar K.J.
        • et al.
        Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
        Oncotarget. 2015; 6: 5615-5633
        • Gary-Gouy H.
        • Harriague J.
        • Bismuth G.
        • Platzer C.
        • Schmitt C.
        • Dalloul A.H.
        Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production.
        Blood. 2002; 100: 4537-4543
        • Gary-Gouy H.
        • Harriague J.
        • Dalloul A.
        • Donnadieu E.
        • Bismuth G.
        CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif.
        J Immunol. 2002; 168: 232-239
        • Alinari L.
        • Gru A.
        • Quinion C.
        • et al.
        De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
        Am J Hematol. 2016; 91: 395-399
        • Thakral B.
        • Medeiros L.J.
        • Desai P.
        • et al.
        Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
        Eur J Haematol. 2017; 98: 415-421
        • Bhatt G.
        • Maddocks K.
        • Christian B.
        CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas.
        Curr Hematol Malig Rep. 2016; 11: 480-491
        • Slack G.W.
        • Steidl C.
        • Sehn L.H.
        • Gascoyne R.D.
        CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
        Br J Haematol. 2014; 167: 608-617
        • Wang X.J.
        • Seegmiller A.C.
        • Reddy N.M.
        • Li S.
        CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.
        Eur J Haematol. 2016; 97: 39-47
        • Xu J.
        • Oki Y.
        • Saksena A.
        • et al.
        CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
        Hum Pathol. 2017; 60: 160-166
        • Epperla N.
        • Hamadani M.
        Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances.
        Hematol Oncol Stem Cell Ther. 2017; Jun 13 (Epub ahead of print). https://doi.org/10.1016/j.hemonc.2017.05.004
        • Wiestner A.
        Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
        J Clin Oncol. 2013; 31: 128-130
        • Bohers E.
        • Mareschal S.
        • Bertrand P.
        • et al.
        Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
        Leuk Lymphoma. 2015; 56: 1213-1222
        • Karmali R.
        • Gordon L.I.
        Molecular subtyping in diffuse large B cell lymphoma: closer to approach of precision therapy.
        Curr Treat Options Oncol. 2017; 18: 11
        • Herrera A.F.
        • Kim H.T.
        • Kong K.A.
        • et al.
        Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma.
        Br J Haematol. 2016; 175: 841-850
        • Rossi D.
        • Diop F.
        • Spaccarotella E.
        • et al.
        Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
        Blood. 2017; 129: 1947-1957